# Vivimed Labs (NSE: VIVIMEDLAB) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/VIVIMEDLAB · Pivot · prices to 22 Oct 2026

Vivimed Labs (NSE: VIVIMEDLAB) closed at ₹6.21 on 22 Oct 2026, down 1.90% on the day. With a market capitalisation of ₹51 Cr, it ranks 3055th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 0.0% in FY25. Over the past year the share price has fallen 45.8%. Its 52-week range is ₹4.75 (11 Aug 2026) to ₹29.40 (18 Dec 2025); the last close is 78.9% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹12 Cr (−53.1% year on year) and net profit −₹147 Cr, on a consolidated basis. Promoters held 7.57% of the company as of 31 Mar 2026; 15.18% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹6.21 |
| Market cap | ₹51 Cr |
| ROE | 0.0% (FY25) |
| ROCE | −5.6% (FY25) |
| Debt to equity | -5.14 |
| 52-week high | ₹29.40 (18 Dec 2025) |
| 52-week low | ₹4.75 (11 Aug 2026) |
| 1-year return | −45.8% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹12 Cr | −53.1% | −₹147 Cr | — | −₹17.74 |
| Q3 FY26 | ₹16 Cr | −56.2% | −₹17 Cr | — | −₹2.00 |
| Q2 FY26 | ₹21 Cr | −16.8% | −₹7 Cr | — | −₹0.88 |
| Q1 FY26 | ₹21 Cr | −27.2% | −₹5 Cr | — | −₹0.66 |
| Q4 FY25 | ₹26 Cr | −33.7% | −₹6 Cr | −206.5% | −₹0.68 |
| Q3 FY25 | ₹37 Cr | −11.9% | −₹6 Cr | — | −₹0.72 |
| Q2 FY25 | ₹25 Cr | −26.4% | −₹5 Cr | — | −₹0.63 |
| Q1 FY25 | ₹29 Cr | −16.9% | −₹15 Cr | — | −₹1.84 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹116 Cr | −₹32 Cr |
| FY24 | ₹149 Cr | −₹45 Cr |
| FY23 | ₹187 Cr | −₹329 Cr |
| FY22 | ₹237 Cr | −₹68 Cr |
| FY21 | ₹861 Cr | −₹72 Cr |
| FY20 | ₹1,059 Cr | −₹109 Cr |

## Shareholding (31 Mar 2026)

- Promoters: 7.57%
- Foreign institutions: 1.64%
- Domestic institutions: 0.00%
- Non-institutions: 90.67%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Kabra Drugs](https://app.pivotnow.in/stock/KABRADG) | — | ₹56 Cr | — | — |
| [Bandaram Pharma](https://app.pivotnow.in/stock/BANDARAM) | — | ₹53 Cr | — | — |
| [Vasundhara Ras](https://app.pivotnow.in/stock/VRL) | — | ₹53 Cr | — | — |
| [Shree Pacetroni](https://app.pivotnow.in/stock/SHREEPAC) | — | ₹50 Cr | — | — |
| [Biofil Chemicals & Pharmaceuticals](https://app.pivotnow.in/stock/BIOFILCHEM) | ₹30.00 | ₹49 Cr | 17.5 | — |
| [Shanmuga Hospit](https://app.pivotnow.in/stock/SHANMUGA) | — | ₹48 Cr | — | — |

## Questions and answers

### What is the share price of Vivimed Labs today?

Vivimed Labs (NSE: VIVIMEDLAB) last closed at ₹6.21 on 22 Oct 2026. Its 52-week high is ₹29.40 and its 52-week low is ₹4.75.

### What is the market cap of Vivimed Labs?

Vivimed Labs' market capitalisation is ₹51 Cr (₹51 Cr) at the 22 Oct 2026 close, ranking 3055th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Vivimed Labs?

Return on equity was 0.0% in FY25 and return on capital employed was −5.6% in FY25 (consolidated figures).

### Is Vivimed Labs a debt-free company?

Vivimed Labs is close to debt-free: its debt-to-equity ratio was -5.14 in FY25.

### What were Vivimed Labs' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Vivimed Labs reported revenue of ₹12 Cr, −53.1% year on year, and net profit of −₹147 Cr.

### How has Vivimed Labs stock performed over the last year?

Vivimed Labs' share price has fallen 45.8% over the past year, +19.7% over three months and +13.5% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Vivimed Labs?

As of 31 Mar 2026: promoters 7.57%, foreign institutions 1.64%, domestic institutions 0.00%, non-institutions 90.67%. 15.18% of promoter shares were pledged.

### Who are Vivimed Labs' competitors?

The listed Pharma & Healthcare companies closest to Vivimed Labs by market cap are Kabra Drugs, Bandaram Pharma, Vasundhara Ras, Shree Pacetroni, Biofil Chemicals & Pharmaceuticals and Shanmuga Hospit.

### Is Vivimed Labs a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Vivimed Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VIVIMEDLAB against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.